MBX Biosciences Common Stock Total Current Liabilities

MBX Biosciences Common Stock (MBX) currently reports a total current liabilities of $15M as of March 2026. That compares with $10M in the prior-year period — up 39.0% year over year. Use the charts on this page to explore MBX Biosciences Common Stock's total current liabilities history and peer comparisons.

MBX Biosciences Common Stock's total current liabilities increased from $10M to $15M — a 39.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MBX Biosciences Common Stock reported $15M in total current liabilities as of March 2026. That compares with $10M in the prior-year period — up 39.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $15M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for MBX Biosciences Common Stock, and consider following MBX for alerts when major investors trade the stock.

MBX Biosciences Common Stock is classified in the Healthcare sector. On total current liabilities, it currently shows $15M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MBX with unrelated industries.